Trials
2 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SYS6017 is an investigational lipid nanoparticle (LNP)-coated mRNA vaccine encoding the glycoprotein E (gE) of VZV, and indicated for active immunization for the prevention of zoster caused by the reactivation of latent VZV.”In the company’s words, NCT06954818 on ClinicalTrials.gov
- Tested for
- Herpes Zoster (2 trials)
- Main trialPhase 2
- “Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. We are conducting a study entitled "A Randomized, Blinded, Placebo- and Active-Controlled, Adaptive Phase 2 Clinical Trial to Evaluate the Immunogenicity and Safety of SYS6017 (a Herpes Zoster mRNA Vaccine) in Healthy Participants Aged 40 Years and Above".”In the company’s words, NCT07354659 on ClinicalTrials.gov
Other drugs for Herpes Zoster
- HZ/su vaccineGSK · Phase 3
- Recombinant Zoster VaccineMAXVAX Biotechnology Limited Liability Company · Phase 3
- CVI-VZV-001Aribio Lab Co., Ltd. · Phase 2
- Z-1018Dynavax Technologies Corporation · Phase 1/2
- SYS6052CSPC · Phase 1/2
- HZ VaccineShenzhen Shenxin Biotechnology Co., Ltd · Phase 2
Coming up1
- 10 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 10 Mar 2027 | Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above | |
| Phase 1Not yet recruiting | 10 Dec 2025 | Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026